Search Results
10
Everything
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
March 27, 2025 15:38 ET
|
Spherix Global Insights
EXTON, PA, March 27, 2025 (GLOBE NEWSWIRE) -- In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu...
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
February 13, 2025 11:55 ET
|
Spherix Global Insights
EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a...
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
January 16, 2025 08:19 ET
|
Biomerica, Inc.
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif.,...
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
September 04, 2024 08:19 ET
|
Biomerica, Inc.
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally ...
World Wildlife Fund Launches New PSA to Combat Plastic Pollution featuring U2 song ‘Beautiful Day’
April 19, 2024 09:15 ET
|
World Wildlife Fund
Washington, DC, April 19, 2024 (GLOBE NEWSWIRE) -- Today, World Wildlife Fund (WWF), the global conservation nonprofit, released a new Public Service Announcement (PSA) ahead of Earth Day (April...
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16, 2024 14:06 ET
|
Spherix Global Insights
EXTON, PA, April 16, 2024 (GLOBE NEWSWIRE) -- In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA),...
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
January 22, 2024 10:47 ET
|
Spherix Global Insights
EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld their...
En tant qu'allié dévoué, le Ruban blanc publie des Vies en Bref qui traitent de la violence à l'encontre des communautés transgenres
November 13, 2023 06:30 ET
|
Ruban blanc
TORONTO, 13 nov. 2023 (GLOBE NEWSWIRE) -- Le Ruban blanc lance sa toute dernière campagne, Vies en Bref, qui suit la vie d'une femme transgenre depuis sa transition. Cette campagne se penche sur son...
As a committed ally, White Ribbon releases Short Life Stories addressing violence against the transgender communities
November 13, 2023 06:30 ET
|
White Ribbon
As a committed ally, White Ribbon releases Short Life Stories addressing violence against the transgender communities.
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
October 03, 2023 13:57 ET
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...